EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A p75 neurotrophin receptor‐sparing nerve growth factor protects retinal ganglion cells from neurodegeneration by targeting microglia

Laura Latini, Daniel Souza Monteiro De Araujo, Rosario Amato, Alessio Canovai, Lucia Buccarello, Francesco De Logu, Elena Novelli, Anastasiia Vlasiuk, Francesca Malerba, Ivan Arisi, Rita Florio, Hiroki Asari und 9 weitere

British Journal of Pharmacology · 2024-12 · 181 (23) · 4890-4919

DOI: 10.1111/bph.17316 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 09.09.2024. Verfasst von Laura Latini und 20 weiteren Autor:innen. Beteiligte Einrichtung: European Brain Research Institute-Fondazione Rita Levi-Montalcini, Rome, Italy. Hauptthemen laut MEDLINE: Retinal Ganglion Cells, Nerve Growth Factor, Microglia, Neuroprotective Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Italian Ministry of Health, Fondo Ordinario Enti, Chiesi Farmaceutici.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Retinal ganglion cells (RGCs) are the output stage of retinal information processing, via their axons forming the optic nerve (ON). ON damage leads to axonal degeneration and death of RGCs, and results in vision impairment. Nerve growth factor (NGF) signalling is crucial for RGC operations and visual functions. Here, we investigate a new neuroprotective mechanism of a novel therapeutic candidate, a p75‐less, TrkA‐biased NGF agonist (hNGFp) in rat RGC degeneration, in comparison with wild type human NGF (hNGFwt). Experimental Approach Both neonate and adult rats, whether subjected or not to ON lesion, were treated with intravitreal injections or eye drops containing either hNGFp or hNGFwt. Different doses of the drugs were administered at days 1, 4 or 7 after injury for a maximum of 10 days, when immunofluorescence, electrophysiology, cellular morphology, cytokine array and behaviour studies were carried out. Pharmacokinetic evaluation was performed on rabbits treated with hNGFp ocular drops. Results hNGFp exerted a potent RGC neuroprotection by acting on microglia cells, and outperformed hNGFwt in rescuing RGC degeneration and reducing inflammatory molecules. Delayed use of hNGFp after ON lesion resulted in better outcomes compared with treatment with hNGFwt. Moreover, hNGFp‐based ocular drops were less algogenic than hNGFwt. Pharmacokinetic measurements revealed that biologically relevant quantities of hNGFp were found in the rabbit retina. Conclusions and Implications Our data point to microglia as a new cell target through which NGF‐induced TrkA signalling exerts neuroprotection of the RGC, emphasizing hNGFp as a powerful treatment to tackle retinal degeneration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Retinal Ganglion CellsNerve Growth FactorMicrogliaNeuroprotective AgentsAnimalsRatsRabbitsIntravitreal InjectionsRats, Sprague-DawleyMaleReceptors, Nerve Growth FactorHumansRetinal Degeneration

Stichwörter der Autor:innen

NGFhNGFpmicrogliaretinal degenerationretinal ganglion cells

Substanzen

Nerve Growth FactorNeuroprotective AgentsReceptors, Nerve Growth Factor

Autor:innen und Institutionen

  • European Brain Research Institute-Fondazione Rita Levi-Montalcini, Rome, Italy.
  • Department of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, Florence, Italy.
  • Department of Biology, University of Pisa, Pisa, Italy.
  • Institute of Neuroscience, Italian National Research Council-CNR, Pisa, Italy.
  • Faculty of Biosciences, Collaboration for Joint PhD Degree Between EMBL and Heidelberg University, Heidelberg, Germany.
  • Epigenetics and Neurobiology Unit, EMBL Rome, European Molecular Biology Laboratory, Rome, Italy.

ORCID-Profile: Massimo Dal Monte, Romina Nassini, Silvia Marinelli

Förderung

  • Italian Ministry of Health
  • Fondo Ordinario Enti
  • Chiesi Farmaceutici
  • Ministero della Salute
  • Center for Neuroscience Research

Zitieren

APA

Latini, L., De Araujo, D. S. M., Amato, R., Canovai, A., Buccarello, L., De Logu, F., Novelli, E., Vlasiuk, A., Malerba, F., Arisi, I., Florio, R., Asari, H., Capsoni, S., Strettoi, E., Villetti, G., Imbimbo, B. P., Dal Monte, M., Nassini, R., Geppetti, P., …, & Cattaneo, A. (2024). A p75 neurotrophin receptor‐sparing nerve growth factor protects retinal ganglion cells from neurodegeneration by targeting microglia. British Journal of Pharmacology, 181(23), 4890-4919. https://doi.org/10.1111/bph.17316

Vancouver

Latini L, De Araujo DSM, Amato R, Canovai A, Buccarello L, De Logu F, et al. A p75 neurotrophin receptor‐sparing nerve growth factor protects retinal ganglion cells from neurodegeneration by targeting microglia. British Journal of Pharmacology. 2024;181(23):4890-4919. doi:10.1111/bph.17316

BibTeX
@article{Latini2024,
  author = {Latini, Laura and De Araujo, Daniel Souza Monteiro and Amato, Rosario and Canovai, Alessio and Buccarello, Lucia and De Logu, Francesco and Novelli, Elena and Vlasiuk, Anastasiia and Malerba, Francesca and Arisi, Ivan and Florio, Rita and Asari, Hiroki and Capsoni, Simona and Strettoi, Enrica and Villetti, Gino and Imbimbo, Bruno Pietro and Dal Monte, Massimo and Nassini, Romina and Geppetti, Pierangelo and Marinelli, Silvia and Cattaneo, Antonino},
  title = {A p75 neurotrophin receptor‐sparing nerve growth factor protects retinal ganglion cells from neurodegeneration by targeting microglia},
  journal = {British Journal of Pharmacology},
  year = {2024},
  volume = {181},
  number = {23},
  pages = {4890--4919},
  doi = {10.1111/bph.17316}
}
Kostenlos starten →